Development and validation of blood tumor mutational burden reference standards

Tumor mutational burden (TMB), measured by exome or panel sequencing of tumor tissue or blood (bTMB), is a potential predictive biomarker for treatment benefit in patients with various cancer types receiving immunotherapy targeting checkpoint pathways. However, significant variability in TMB measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Raiber‐Moreau, Eun‐Ang, Portella, Guillem, Butler, Matthew G., Clement, Omoshile, Konigshofer, Yves, Hadfield, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107199/
https://www.ncbi.nlm.nih.gov/pubmed/36326821
http://dx.doi.org/10.1002/gcc.23100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107199/
https://www.ncbi.nlm.nih.gov/pubmed/36326821
http://dx.doi.org/10.1002/gcc.23100

Ejemplares similares